EU-FDA MRA to be expanded
Recommendation

27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
It has not yet been fully implemented - and we are already talking about an enlargement. The Mutual Recognition Agreement (MRA) with the USA was extended in 2018 to include further countries: Czech Republic, Greece, Hungary, Romania, Ireland, Lithuania, Portugal, Belgium, Denmark, Estonia, Finland, Latvia. Some countries, including Germany, are still not part of the agreement. (Here you will find an overview of the current status). By 15 July 2019, however, all authorities and countries should have been approved and included.
Now, there are already discussions about extending the scope of the MRA. It is to be extended to veterinary medicinal products in the medium term. Later, until 2022, the MRA is to be extended to include joint inspections of production facilities for human vaccines and plasma derivatives. An action plan will be drawn up for this purpose in 2019. This is stated in an interim report of the Executive Working Group EWG.
Related GMP News
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published
11.03.2026FDA Guidance Plans for 2026


